Soleno Therapeutics Receives Bullish Rating from Guggenheim, Price Target Raised to $106.00

Guggenheim analyst Debjit Chattopadhyay raised the price target for Soleno Therapeutics (SLNO) to $106.00 from $97.00, maintaining a "Buy" rating. This follows a series of upward adjustments from other analysts, reflecting optimism about SLNO's prospects. The average target price for SLNO is $116.44, with a high estimate of $145.00 and a low estimate of $100.00, implying an upside of 43.58% from the current price.

July 02, 2025

Guggenheim analyst Debjit Chattopadhyay has raised the price target for Soleno Therapeutics (SLNO) to $106.00 from $97.00, maintaining a "Buy" rating. This move follows a series of upward adjustments from other analysts, indicating a positive outlook on the biopharmaceutical company's prospects. The average target price for SLNO is $116.44, with a high estimate of $145.00 and a low estimate of $100.00, implying an upside of 43.58% from the current price of $81.10.

Historically, SLNO has seen consistent upward adjustments in price targets. On July 11, 2025, Baird analyst Brian Skorney maintained an 'Outperform' rating, raising the price target from $105.00 to $121.00. On May 8, 2025, the same analyst increased the price target from $102.00 to $105.00. Additionally, Guggenheim's Debjit Chattopadhyay maintained a 'Buy' rating, elevating the price target from $81.00 to $97.00 on May 8, 2025.

Soleno Therapeutics, Inc. is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate, DCCR (Diazoxide Choline) Extended-Release tablets, has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's recent FDA approval of VYKATTM XR for Prader-Willi syndrome (PWS) has been well-received, with over 100 million lives covered and significant market potential.

The company reported its second-quarter 2025 financial results, including $32.7 million in product revenue and a net loss of $4.7 million. The company's cash position has improved, with $293.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025, following a $230 million gross proceeds raise through an underwritten offering of common stock.

Analysts' optimism is supported by the company's strong pipeline and recent regulatory approvals. Soleno's continued efforts to raise awareness of VYKAT XR's efficacy and safety profile through data presentations at leading medical meetings further underscore its commitment to the PWS community.

References:

[1] https://www.gurufocus.com/news/3045339/slno-guggenheim-raises-price-target-amidst-continued-buy-rating-slno-stock-news
[2] https://www.biospace.com/press-releases/soleno-therapeutics-provides-update-on-u-s-launch-of-vykattm-xr-and-reports-second-quarter-2025-financial-results